Congratulations to our longstanding client, Enlivex Therapeutics Ltd. (“Enlivex”, NASDAQ: ENLV), which recently announced the successful completion of a $51.3 million offering of its Ordinary Shares. Leading the transaction on behalf of GT are Bob Grossman, Chair of Greenberg Traurig’s Israel Practice and senior M&A and financing attorney at the firm’s Miami office, together with Drew Altman, Chair of the Miami Corporate Practice with considerable experience in Israeli transactions, and Win Rutherfurd, Miami Corporate attorney. The GT team in Miami, together with support from Aaron Katz, Corporate Tel Aviv attorney, represented Enlivex on its 2019 merger through which the company became a public company in the United States. Additionally, the GT team in Miami represented the company on two registered direct offerings, one ATM offering and one underwritten offering during the past 12 months.
Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. AllocetraTM is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.
H.C. Wainwright & Co. acted as the sole book-running manager for all four offerings.
Click here to view the full press release.